Assessment of the Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Systemic Therapy and Surgery, UTMOST Trial
Study Details
Study Description
Brief Summary
This phase I study assesses the safety, ultrasound visibility (conspicuity), and movement from normal position (migration) of the twinkling marker in patients with breast cancer that has spread to the axillary lymph nodes (locally advanced) who will be undergoing neoadjuvant systemic therapy and surgery. Biopsy markers are used to identify the sites of cancer involvement in both the breasts and lymph nodes. These biopsy markers are needed to help guide breast cancer surgery. Twinkling markers are designed to have the same size and shape of conventional biopsy markers, but are made of a radio-opaque material that assists with localization of the marker. The twinkling marker may make it more easily seen with ultrasound at the time of breast cancer surgery as compared to conventional biopsy markers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
PRIMARY OBJECTIVE:
- To show that the biologically inert, Food and Drug Administration (FDA)-approved material that comprises the Mayo-developed twinkling marker (Patent Application Title: Non-Metallic
Ultrasound-Detectable Markers Patent Application No.: 62/903,078, Application Type:
Provisional) remains conspicuous under ultrasound after neoadjuvant systemic therapy in patients with clinically node-positive breast cancer.
SECONDARY OBJECTIVE:
- To evaluate the safety and migration of the Mayo-designed twinkling marker in patients during neoadjuvant systemic therapy (NST).
OUTLINE:
Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker throughout the trial. Patients undergo a breast ultrasound during screening, on study, and as clinically indicated. Patient also undergoes a mammogram on study and as clinically indicated as well as a magnetic resonance imaging (MRI) as clinically indicated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Observational (twinkle marker placement) Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker throughout the trial. Patients undergo a breast ultrasound during screening, on study, and as clinically indicated. Patient also undergoes a mammogram on study and as clinically indicated as well as a MRI as clinically indicated. |
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
Procedure: Mammogram
Undergo a mammogram
Procedure: Ultrasound
Undergo a breast ultrasound
Procedure: Ultrasound-Guided Biopsy
Undergo a percutaneous ultrasound-guided breast clip placement
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Long-term efficacy of the twinkling marker [through study completion, an average of 4 months]
The primary outcome is information on the long-term efficacy of the twinkling marker in humans placed in the lymph nodes of patients undergoing neoadjuvant systemic therapy (NST) for breast cancer. The data will explore the presence/absence of the twinkling artifact associated with the twinkling marker under ultrasound.
Secondary Outcome Measures
- Determination of safety and migration of the twinkling marker [through study completion, an average of 4 months]
The secondary outcome is determination of safety and migration of the Mayo-designed twinkling marker in patients after NST. Clinical notes will be reviewed to assess for any complications related to the twinkling marker during NST. Migration will be determined from surgical and pathology documentation.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node
-
Surgical management will be determined by Dr. Mara Piltin, who will decide if preoperative I-125 seed localization of the positive node is necessary or if she will retrieve the positive node with intraoperative ultrasound guidance. During surgery, the targeted node, its associated biopsy markers, I-125 seed if placed, and twinkling marker will be resected. The position of the marker in the lymph node or proximity to the node will be noted from the surgical and pathology documentation.
-
Surgery will be performed by Dr. Mara Piltin
-
Patients must be able to understand the study procedures and comply with them for the entire length of the study
-
No contraception is necessary or required
Exclusion Criteria:
-
Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
-
Inability or unwillingness of individual or legal guardian/representative to give written informed consent
-
Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Christine U Lee, Mayo Clinic in Rochester
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 22-002857
- NCI-2022-06278
- 22-002857
- P30CA015083